Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes

A. Crispo, L. S A Augustin, M. Grimaldi, Flavia Nocerino, A. Giudice, E. Cavalcanti, M. Di Bonito, G. Botti, M. De Laurentiis, M. Rinaldo, E. Esposito, G. Riccardi, A. Amore, M. Libra, G. Ciliberto, D. J A Jenkins, M. Montella

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hyperglycemia and hyperinsulinemia may play a role in breast carcinogenesis and prediabetes and diabetes have been associated with increased breast cancer (BC) risk. However, whether BC molecular subtypes may modify these associations is less clear. We therefore investigated these associations in all cases and by BC molecular subtypes among women living in Southern Italy. Cases were 557 patients with non-metastatic incident BC and controls were 592 outpatients enrolled during the same period as cases and in the same hospital for skin-related non-malignant conditions. Adjusted multivariate logistic regression models were built to assess the risks of developing BC in the presence of prediabetes or diabetes. The analyses were repeated by strata of BC molecular subtypes: Luminal A, Luminal B, HER2+, and Triple Negative (TN). Prediabetes and diabetes were significantly associated with higher BC incidence after controlling for known risk factors (OR = 1.94, 95% CI 1.32–2.87 and OR = 2.46, 95% CI 1.38–4.37, respectively). Similar results were seen in Luminal A and B while in the TN subtype only prediabetes was associated with BC (OR = 2.43, 95% CI 1.11–5.32). Among HER2+ patients, only diabetes was significantly associated with BC risk (OR = 3.04, 95% CI 1.24–7.47). Furthermore, when postmenopausal HER2+ was split into hormone receptor positive versus negative, the association with diabetes remained significant only in the former (OR = 5.13, 95% CI 1.53–17.22). These results suggest that prediabetes and diabetes are strongly associated with BC incidence and that these metabolic conditions may be more relevant in the presence of breast cancer molecular subtypes with positive hormone receptors. J. Cell. Physiol. 232: 1144–1150, 2017.

Original languageEnglish
Pages (from-to)1144-1150
Number of pages7
JournalJournal of Cellular Physiology
Volume232
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Prediabetic State
Medical problems
Breast Neoplasms
Hormones
Logistics
Skin
Logistic Models
Incidence
Hyperinsulinism
Hyperglycemia
Italy
Carcinogenesis
Breast
Outpatients

ASJC Scopus subject areas

  • Medicine(all)
  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes. / Crispo, A.; Augustin, L. S A; Grimaldi, M.; Nocerino, Flavia; Giudice, A.; Cavalcanti, E.; Di Bonito, M.; Botti, G.; De Laurentiis, M.; Rinaldo, M.; Esposito, E.; Riccardi, G.; Amore, A.; Libra, M.; Ciliberto, G.; Jenkins, D. J A; Montella, M.

In: Journal of Cellular Physiology, Vol. 232, No. 5, 01.05.2017, p. 1144-1150.

Research output: Contribution to journalArticle

@article{bd149b2612334af794d1f91cd3b65f6d,
title = "Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes",
abstract = "Hyperglycemia and hyperinsulinemia may play a role in breast carcinogenesis and prediabetes and diabetes have been associated with increased breast cancer (BC) risk. However, whether BC molecular subtypes may modify these associations is less clear. We therefore investigated these associations in all cases and by BC molecular subtypes among women living in Southern Italy. Cases were 557 patients with non-metastatic incident BC and controls were 592 outpatients enrolled during the same period as cases and in the same hospital for skin-related non-malignant conditions. Adjusted multivariate logistic regression models were built to assess the risks of developing BC in the presence of prediabetes or diabetes. The analyses were repeated by strata of BC molecular subtypes: Luminal A, Luminal B, HER2+, and Triple Negative (TN). Prediabetes and diabetes were significantly associated with higher BC incidence after controlling for known risk factors (OR = 1.94, 95{\%} CI 1.32–2.87 and OR = 2.46, 95{\%} CI 1.38–4.37, respectively). Similar results were seen in Luminal A and B while in the TN subtype only prediabetes was associated with BC (OR = 2.43, 95{\%} CI 1.11–5.32). Among HER2+ patients, only diabetes was significantly associated with BC risk (OR = 3.04, 95{\%} CI 1.24–7.47). Furthermore, when postmenopausal HER2+ was split into hormone receptor positive versus negative, the association with diabetes remained significant only in the former (OR = 5.13, 95{\%} CI 1.53–17.22). These results suggest that prediabetes and diabetes are strongly associated with BC incidence and that these metabolic conditions may be more relevant in the presence of breast cancer molecular subtypes with positive hormone receptors. J. Cell. Physiol. 232: 1144–1150, 2017.",
author = "A. Crispo and Augustin, {L. S A} and M. Grimaldi and Flavia Nocerino and A. Giudice and E. Cavalcanti and {Di Bonito}, M. and G. Botti and {De Laurentiis}, M. and M. Rinaldo and E. Esposito and G. Riccardi and A. Amore and M. Libra and G. Ciliberto and Jenkins, {D. J A} and M. Montella",
year = "2017",
month = "5",
day = "1",
doi = "10.1002/jcp.25579",
language = "English",
volume = "232",
pages = "1144--1150",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Risk Differences Between Prediabetes And Diabetes According To Breast Cancer Molecular Subtypes

AU - Crispo, A.

AU - Augustin, L. S A

AU - Grimaldi, M.

AU - Nocerino, Flavia

AU - Giudice, A.

AU - Cavalcanti, E.

AU - Di Bonito, M.

AU - Botti, G.

AU - De Laurentiis, M.

AU - Rinaldo, M.

AU - Esposito, E.

AU - Riccardi, G.

AU - Amore, A.

AU - Libra, M.

AU - Ciliberto, G.

AU - Jenkins, D. J A

AU - Montella, M.

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Hyperglycemia and hyperinsulinemia may play a role in breast carcinogenesis and prediabetes and diabetes have been associated with increased breast cancer (BC) risk. However, whether BC molecular subtypes may modify these associations is less clear. We therefore investigated these associations in all cases and by BC molecular subtypes among women living in Southern Italy. Cases were 557 patients with non-metastatic incident BC and controls were 592 outpatients enrolled during the same period as cases and in the same hospital for skin-related non-malignant conditions. Adjusted multivariate logistic regression models were built to assess the risks of developing BC in the presence of prediabetes or diabetes. The analyses were repeated by strata of BC molecular subtypes: Luminal A, Luminal B, HER2+, and Triple Negative (TN). Prediabetes and diabetes were significantly associated with higher BC incidence after controlling for known risk factors (OR = 1.94, 95% CI 1.32–2.87 and OR = 2.46, 95% CI 1.38–4.37, respectively). Similar results were seen in Luminal A and B while in the TN subtype only prediabetes was associated with BC (OR = 2.43, 95% CI 1.11–5.32). Among HER2+ patients, only diabetes was significantly associated with BC risk (OR = 3.04, 95% CI 1.24–7.47). Furthermore, when postmenopausal HER2+ was split into hormone receptor positive versus negative, the association with diabetes remained significant only in the former (OR = 5.13, 95% CI 1.53–17.22). These results suggest that prediabetes and diabetes are strongly associated with BC incidence and that these metabolic conditions may be more relevant in the presence of breast cancer molecular subtypes with positive hormone receptors. J. Cell. Physiol. 232: 1144–1150, 2017.

AB - Hyperglycemia and hyperinsulinemia may play a role in breast carcinogenesis and prediabetes and diabetes have been associated with increased breast cancer (BC) risk. However, whether BC molecular subtypes may modify these associations is less clear. We therefore investigated these associations in all cases and by BC molecular subtypes among women living in Southern Italy. Cases were 557 patients with non-metastatic incident BC and controls were 592 outpatients enrolled during the same period as cases and in the same hospital for skin-related non-malignant conditions. Adjusted multivariate logistic regression models were built to assess the risks of developing BC in the presence of prediabetes or diabetes. The analyses were repeated by strata of BC molecular subtypes: Luminal A, Luminal B, HER2+, and Triple Negative (TN). Prediabetes and diabetes were significantly associated with higher BC incidence after controlling for known risk factors (OR = 1.94, 95% CI 1.32–2.87 and OR = 2.46, 95% CI 1.38–4.37, respectively). Similar results were seen in Luminal A and B while in the TN subtype only prediabetes was associated with BC (OR = 2.43, 95% CI 1.11–5.32). Among HER2+ patients, only diabetes was significantly associated with BC risk (OR = 3.04, 95% CI 1.24–7.47). Furthermore, when postmenopausal HER2+ was split into hormone receptor positive versus negative, the association with diabetes remained significant only in the former (OR = 5.13, 95% CI 1.53–17.22). These results suggest that prediabetes and diabetes are strongly associated with BC incidence and that these metabolic conditions may be more relevant in the presence of breast cancer molecular subtypes with positive hormone receptors. J. Cell. Physiol. 232: 1144–1150, 2017.

UR - http://www.scopus.com/inward/record.url?scp=85009765334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009765334&partnerID=8YFLogxK

U2 - 10.1002/jcp.25579

DO - 10.1002/jcp.25579

M3 - Article

VL - 232

SP - 1144

EP - 1150

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 5

ER -